Session Title: AMD II
Session Date/Time: Friday 18/09/2015 | 14:30-16:00
Paper Time: 15:42
First Author: : G.Zhurgumbaeyva KAZAKHSTAN
Co Author(s): : T. Botabelkova G. Zhurgumbaeva N. Aldasheva N. Aldasheva L. Muraveva
PURPOSE:To estimate efficiency of intravitreal injections of aflibercept in patients with wet AMD.
Age-related macular degeneration (AMD) is the main reason for a blindness in the developed countries. Aflibertsept 'Eylea', a recombinant hybrid protein that inhibiting all isoforms of VEGF-A, is approved for the treatment of the wet form of AMD.
Material and methods. Under supervision there were 18 patients (18 eyes) with the wet form of AMD. The median age was 62,7 ± 5,7 years. maximum correcting visual acuity (MCVA) before injection ranged from 0.04 to 0.1 (average of 0,06 ± 0,02). Retinal thickness at the center according to the OST from 303 to 509 microns (average 419 ± 68mk). All patients received 3 loading injections of 'Eylea' with a difference in a month by a standard method. In all cases in the postoperative period for 2 days appointed by carbonic anhydrase inhibitors in the instillation of 5 days - a combination of antibacterial and anti-inflammatory drugs. Monitoring between injections was not performed.
Complications of inflammatory character and a postoperative ocular hypertension wasn't observed. All patients for the first days after an injection subjectively noted reduction of distortion of the image, contrast increase. MCVA after 3 injections raised in all cases and averaged 0,3 ± 0,09 (0.1 to 0.65) The thickness of the retina at the center according to OST decreased in all patients, averaging 290 ± 46 microns ( from 227 to 368 microns).
Intravitreal injection of 'Eylea' is an effective in the treatment of the wet form of AMD, promoting reduction of thickness of a retina in the center by 1,4 times and raises MCVA by 5 times.